# Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
Canonical URL: https://biopharmsignal.com/news/MDNA/medicenna-strengthens-u-s-patent-estate-with-newly-issued-and-allowed-patents-across-its-il-2-il-4-and-il-13-superkine-platforms
Ticker: MDNA
Company: Medicenna Therapeutics Corp.
Source: Medicenna Therapeutics Corp.
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.medicenna.com
## Summary

New U.S. patents extend protection for cellular immunotherapy applications, immune cell targeting constructs and bizaxofusp combination therapy with anti-VEGF agents for CNS tumors; global portfolio now exceeds 100 active granted patents and applications TORONTO, June 11, 2026 (GLOBE NEWSWIRE) --

## Article Body
New U.S. patents extend protection for cellular immunotherapy applications, immune cell targeting constructs and bizaxofusp combination therapy with anti-VEGF agents for CNS tumors; global portfolio now exceeds 100 active granted patents and applications TORONTO, June 11, 2026 (GLOBE NEWSWIRE) --
## Recent Company News
- 2026-06-26 12:45 EST — [Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights](https://biopharmsignal.com/news/MDNA/medicenna-therapeutics-reports-fiscal-year-2026-financial-results-and-operationa-270c22c3) — Source: Medicenna Therapeutics Corp.
- 2026-06-25 13:46 EST — [Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms](https://biopharmsignal.com/news/MDNA/medicenna-strengthens-u-s-patent-estate-with-newly-issued-and-allowed-patents-across-its-il-2-il-4-and-il-13-superkine-platforms) — Source: Medicenna Therapeutics Corp.
- 2026-06-25 13:46 EST — [Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026](https://biopharmsignal.com/news/MDNA/medicenna-s-mdna11-potential-in-earlier-line-melanoma-setting-highlighted-in-presentation-of-the-neo-cyt-trial-at-asco-2026) — Source: Medicenna Therapeutics Corp.
- 2026-06-25 13:46 EST — [Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs](https://biopharmsignal.com/news/MDNA/medicenna-announces-closing-of-public-offering-of-units-raising-cdn-4-44-million-to-support-lead-programs) — Source: Medicenna Therapeutics Corp.
- 2026-06-25 13:46 EST — [Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet](https://biopharmsignal.com/news/MDNA/medicenna-announces-the-filing-of-its-prospectus-supplement-and-investment-term-sheet) — Source: Medicenna Therapeutics Corp.
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)